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Postpartum Management of Women
Begun on Levothyroxine during
Pregnancy
Alex Stagnaro-Green*
University of Illinois Rockford College of Medicine, Rockford, IL, USA
During pregnancy, the thyroid glandmust produce 50%more thyroid hormone tomaintain
the euthyroid state. Women with decreased thyroid reserve preconception, most typically
due to Hashimoto’s thyroiditis, may develop hypothyroidism during pregnancy. Data over
the last 20 years have reported a strong association between subclinical hypothyroidism
and adverse maternal/fetal events. As a result of this association, an increasing number
of women are being screened for thyroid disease either preconception or at the first
prenatal visit. Consequently, an ever increasing number of women are being initiated
on levothyroxine for the first time during pregnancy. At present, there are very limited
guidelines related to the management of the thyroid disease in these women postpartum.
Based on an understanding of the physiology of the thyroid gland during pregnancy and
postpartum, and the personal clinical experience of the author, recommendations for the
postpartummanagement of women who were started on levothyroxine during pregnancy
are presented.
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Pregnancy has a profound impact on the thyroid gland and on thyroid function (1). Estrogen
levels, which are elevated during pregnancy, result in a dramatic increase in thyroxine binding
globulin. Increased thyroxine-binding globulin levels, transplacental transfer of thyroxine, and
changes in deiodinase activity, necessitate a 50% rise in total thyroxine production so as to maintain
adequate levels of free thyroid hormone (2). Women with a normal functioning thyroid gland
remain euthyroid throughout pregnancy due to this compensatorymechanism. Pregnancy therefore
teaches us that the healthy thyroid gland has significant reserve as it can accommodate up to the
50% increase in thyroid hormone production while maintaining the euthyroid state. On the other
hand, women with decreased thyroidal reserve preconception, most typically due to Hashimoto’s
thyroiditis, may develop subclinical hypothyroidism during pregnancy (3). Furthermore, women
with unidentified subclinical hypothyroidism preconception may progress to overt hypothyroidism
once pregnant. In essence, pregnancy serves as a stress test for the thyroid gland (Figure 1), bringing
out hypothyroidism in women with underlying thyroid disease.
Screening for thyroid disease during pregnancy, although still the subject of much debate (4), is
increasing in frequency. The incidence of screening varies widelywith surveys ofmembers of thyroid
associations around the world revealing that 21–69% of respondents support universal screening
(5–7). The increase in screeningmirrors accumulating evidence fromobservational studies that sub-
clinical hypothyroidism is associated with multiple adverse maternal and fetal outcomes including
miscarriage (8), gestational hypertension (9), gestational diabetes (10), and preterm delivery (11).
Nevertheless, most professional societies do not recommend universal thyroid screening during
pregnancy due to the limited and mixed results of studies prospectively evaluating the impact of
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FIGURE 1 | Pregnancy-thyroid stress test. Pictorial representation of the
fact that during pregnancy, the thyroid gland mostly secretes 50% more
hormone than the non-pregnant state, and therefore pregnancy represents a
stress test for the thyroid.
levothyroxine treatment of subclinical hypothyroidism during
pregnancy on maternal and fetal outcomes (12, 13). It is therefore
not surprising that in 2011, the American Thyroid Association
guidelines stated that, “There is insufficient evidence to recom-
mend for or against universal TSH screening at the first trimester
visit” (14), whereas the 2012 Endocrine Society Guidelines stated
that, “The committee could not reach agreement with regard to
screening recommendations for all newly pregnant women” (15).
Similarly, the American College of Obstetricians and Gynecol-
ogists does not recommend universal screening (16). However,
recently universal screening for thyroid disease during pregnancy
is being recommended by some associations and researchers
in the field based on the importance of detecting and treating
overt hypothyroidism. The rationale is based on the frequency
of overt hypothyroidism during pregnancy (incidence 0.5–1.0%)
(17), the link to adverse outcomes, which can be prevented with
levothyroxine therapy (18), and studies documenting its cost-
effectiveness (19, 20). Proponents of universal thyroid screening
during pregnancy include the Spanish Endocrine Society (21),
the Indian Endocrine Society (22), and various researchers in the
field (23, 24). Interestingly, the 2014 European Thyroid Associa-
tion Guidelines do not recommend universal screening to detect
subclinical hypothyroidism, but a majority of the authors rec-
ommended universal screening to detect overt hypothyroidism
(25).
Thyroid dysfunction during pregnancy is common. As noted,
earlier studies that screened all pregnant women for thyroid
dysfunction identify 0.5–1.0% of women with overt hypothy-
roidism (elevated TSH and decreased free T4) (17). Studies
screening for subclinical hypothyroidism (elevated TSH and
normal free T4) have yielded an incidence that varies widely.
Early studies, utilizing a TSH cutoff of >4.0mIU/L, reported
an incidence of SCH between 2 and 3% (11). However, recent
studies, which utilized a TSH normal upper limit in the first
trimester of 2.5mIU/L, have reported an incidence as high
as 15.5% (26).
Given the increased frequency with which women are screened
for thyroid dysfunction during pregnancy and the incidence of
OH and SCH, an ever increasing number of women are being
identified for the first time with thyroid dysfunction during preg-
nancy. Furthermore, between 10 and 20% of all pregnant women
are either thyroid peroxidase or thyroglobulin antibody positive
(thyroid antibody positive) and euthyroid. Both the American
Thyroid Association and Endocrine Society recommend that all
thyroid antibody positive first trimester pregnant women with
a TSH >2.5mIU/L should be placed on levothyroxine. Both
societies also recommend levothyroxine therapy in all pregnant
women with a TSH>10.0mIU/L, irrespective of the thyroid anti-
body status or free T4 level. The Endocrine Society also recom-
mends levothyroxine therapy for first trimester antibody negative
women with SCH whereas the American Thyroid Association
concluded that there is insufficient evidence either for or against
levothyroxine intervention in thyroid antibody negative women.
Neither society recommends levothyroxine therapy in pregnant
euthyroid women who are thyroid antibody positive. At present,
only one prospective study has been published in this population,
although the results of that study revealed a decrease in both
miscarriage and preterm delivery (27) The American College
of Obstetricians and Gynecologists recommends levothyroxine
therapy for overt hypothyroidism during pregnancy but does not
recommend levothyroxine treatment for SCH or thyroid antibody
positivity in euthyroid women (16).
As there are disparate recommendations frommedical societies
regarding levothyroxine treatment for SCH during pregnancy, it
would be instructive to know how often clinicians begin levothy-
roxine therapy once SCH is diagnosed. A number of surveys
have been performed in which physicians are presented with
case scenarios of thyroid dysfunction during pregnancy with the
goal of identifying the conditions under which levothyroxine
would be initiated (5–7, 28). In surveys of endocrinologists, the
majority would initiate therapy in a women whose TSH exceeded
2.5mIU/ml and who were thyroid peroxidase positive, whereas
approximately half of the respondents would begin thyroid hor-
mone if the TSH was above 2.5mIU/ml in thyroid antibody
negative women.
Given the above, it can be concluded that there are many
women in which levothyroxine is initiated during pregnancy.
Based on clinical guidelines, it can be assumed that endocrinolo-
gists are more likely to initiate therapy for SCH than obstetricians.
As no professional society at this point recommends therapy for
euthyroid thyroid antibody positive pregnant women, it can be
concluded that the vast majority of women in this category do not
receive levothyroxine. However, given the decreased miscarriage
rates in euthyroid thyroid antibody positive women treated with
levothyroxine reported by Negro et al. (28), it can be assumed
that a percentage of women with multiple miscarriages who are
euthyroid and thyroid antibody positivity are given levothyroxine.
Finally, all women with OH identified during pregnancy receive
levothyroxine.
An important clinical question regards the optimal man-
agement of hypothyroidism postpartum in women begun on
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levothyroxine therapy during pregnancy. This question has
become increasingly relevant asmore women have been identified
with OH and SCH during pregnancy, and therefore, more women
have been started on levothyroxine during gestation. This area
has received limited attention by existing guidelines. Only the
European Thyroid Association Guidelines consider this issue and
do so with a focus solely on thyroid antibody negative pregnant
women started on levothyroxine for a TSH<5mIU/L (25). In this
subset of women, the ETA Guidelines recommend to discontinue
levothyroxine postpartum and check a TSH at 6weeks postpar-
tum. As no prospective studies have investigated this issue, the
remainder of the article will define various postpartum scenarios
and provide recommendations based on the physiology of the
thyroid gland during pregnancy and postpartum and the clinical
practice of the present author.
I utilize a number of principles to guide levothyroxine decisions
postpartum. First of all, the higher the initial TSH during preg-
nancy at the time of diagnosis, the more likely that levothyroxine
will be required to maintain euthyroidism postpartum. Second,
and in many respects, a corollary of the first principle is the
higher the dose of levothyroxine required during pregnancy to
achieve euthyroidism, the more likely that levothyroxine will be
required postpartum. Third, hypothyroid womenwhowere found
to be thyroid antibody positive during pregnancy are more likely
to require levothyroxine postpartum than hypothyroid women
who are thyroid antibody negative. Fourth, complicating post-
partum management in thyroid antibody positive women is the
possibility of postpartum thyroiditis (PPT). Finally, the article by
Shields et al. is instructive as it presents thyroid function tests
at 5 years postpartum in women who had subclinical hypothy-
roidism (TSH> 3mIU/L) at 28weeks gestation (29). The major-
ity of women (75%) were euthyroid at 5 years, with persistent
hypothyroidism (as determined by a TSH>4.5mIU/L or ongoing
levothyroxine therapy) seen more frequently in women who were
thyroid antibody positive or had a TSH >5mIU/L at 28weeks
gestation.
OVERT HYPOTHYROIDISM DIAGNOSED
DURING PREGNANCY – IRRESPECTIVE
OF THYROID ANTIBODY STATUS
Women with overt hypothyroidism initially diagnosed during
pregnancy comprise between 0.5 and 1.0% of pregnant women.
The majority of these women will be thyroid antibody positive.
Once diagnosed, the recommendation is to provide a dose of
levothyroxine, which will optimize the TSH level in the shortest
period of time. Abalovich et al. performed a retrospective study,
which evaluated the dose of levothyroxine needed to treat different
degrees of new onset hypothyroidism in pregnancy. Based on
their data of 12 women, Abalovich and colleagues concluded that
women with newly diagnosed overt hypothyroidism in pregnancy
should be started on a dose of levothyroxine of 2.33μg/kg/day
(30). In general, my practice is to initiate therapy with a dose
of ~100μg/day and to reevaluate the regimen with a TSH at
4–6weeks.
In deciding on a postpartum dose of levothyroxine, I postulate
that at a minimum, the patient had subclinical hypothyroidism
pregestation, which progressed to overt hypothyroidism dur-
ing pregnancy. It is also feasible that the patient had overt
hypothyroidism pregestation, which worsened once pregnancy
was achieved. The final scenario, although least likely, is that
the patient was euthyroid pregestation but had minimal abil-
ity, due to underlying Hashimoto’s disease, to compensate to
the increased demand for thyroid production during pregnancy.
Given all these scenarios, it is reasonable to assume that levothy-
roxine will be required postpartum to maintain euthyroidism.
It can also be assumed that the postpartum dose of levothyrox-
ine required following delivery is less than the dose needed to
maintain euthyroidism in the third trimester. Consequently, I
recommend that immediately postpartum, the levothyroxine dose
be decreased to two-thirds of the final dose administered during
gestation. Follow-up thyroid function tests should be performed
at the first postpartum visit, which is typically at 6 weeks following
delivery.
SUBCLINICAL HYPOTHYROIDISM –
THYROID ANTIBODY POSITIVE
Women with subclinical hypothyroidism initially diagnosed dur-
ing pregnancy comprise between 2 and 15% of pregnant women.
Many, but not all, of these women will be thyroid antibody pos-
itive. Once diagnosed, the recommendation in thyroid antibody
positive women of both the American Thyroid Association and
Endocrine Society is to begin levothyroxine therapy. The study by
Abalovich et al. based its initial treatment recommendations on
the level of TSH at diagnosis and did not take thyroid antibody
status into consideration. Specifically, the recommendation was to
initiate levothyroxine at a dose of 1.20μg/kg/day in women with a
TSH 4.2mIU/L and 1.42μg/kg/day if the TSH is between 4.2
and 10.0mIU/L (30). My practice is to begin treatment with a
levothyroxine dose of between 50 and 75μg/day and to reassess
the TSH in 4–6weeks.
In deciding on a postpartum dose of levothyroxine, I postulate
that prior to pregnancy, the patient had underlying Hashimoto’s
thyroiditis (based on the presence of thyroid antibodies dur-
ing pregnancy) and was either euthyroid with limited reserve
or already had subclinical hypothyroidism. At present, literature
does not exist informing us what percentage of women diag-
nosed with subclinical hypothyroidism in gestation were euthy-
roid prior to pregnancy and what percentage already had sub-
clinical hypothyroidism. In making a therapeutic decision for
this group of women, I make treatment decisions under the
assumption that it is best to avoid subclinical hypothyroidism
in the immediate postpartum when the woman is lactating and
adjusting to the rigors of life with a newborn. Therefore, I
recommend that all women in this group be maintained on
levothyroxine in the immediate postpartum. Once again, it can
be assumed that the dose of levothyroxine required following
delivery is less than the dose needed to maintain euthyroidism
in the third trimester. Consequently, I would recommend that
immediately postpartum, the levothyroxine dose be decreased to
half of the final dose administered during gestation. Follow-up
thyroid function tests should be performed at the first postpartum
visit.
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SUBCLINICAL HYPOTHYROIDISM –
THYROID ANTIBODY NEGATIVE
As noted in the prior section, women with subclinical hypothy-
roidism initially diagnosed during pregnancy comprise between
2 and 15% of pregnant women. Although the majority of these
women will be thyroid antibody positive, a distinct minority
will be thyroid antibody negative. These women may be truly
thyroid antibody negative or may have become antibody nega-
tive as a result of the immunosuppressive impact of pregnancy.
Management recommendations in this group of women differ,
with the Endocrine Society recommending that all pregnant
women with subclinical hypothyroidism receive levothyroxine
irrespective of their thyroid antibody status, whereas the Amer-
ican Thyroid Association states that there is insufficient data
to make a recommendation. As noted above, Abalovich et al.
recommend the following levothyroxine algorithm to initiate
therapy in pregnant women with new onset subclinical hypothy-
roidism – 1.20μg/kg/day in womenwith a TSH4.2mIU/ml and
1.42μg/kg/day if the TSH is between 4.2 and 10.0mIU/ml. It is,
therefore, likely that all of these women will be on a minimum
of 50mcg of levothyroxine daily at delivery. My practice is to
begin with 25μg/day of levothyroxine if the TSH is between 2.5
and 5.0mIU/ml and 50μg if the TSH exceeds 5.0mIU/ml. Once
the TSH approaches 10.0mIU/ml, I recommend, at a minimum,
75μg/day of levothyroxine.
In deciding on a postpartum course of therapy, I utilize as a
guide the maximal dose of levothyroxine required during preg-
nancy to maintain the euthyroid state. In women who required
a maximal dose of 25mcg, I routinely discontinue levothyrox-
ine immediately postpartum. When the maximal dose during
pregnancy was 50mcg of levothyroxine, I decrease the dose to
25mcg immediately following delivery. In women who require
a maximum pregnancy dose of 75 or 100mcg, I initiate 50mcg
of levothyroxine immediately postpartum. In those rare circum-
stances where more than 100mcg of levothyroxine is needed
during gestation, I recommend the postpartum dose to be 50%
of the maximum pregnancy dose. At 6-week follow-up, I evaluate
TSH, free T4, and repeat thyroid antibodies, as some of these
women probably were thyroid antibody positive pregestation.
ISOLATED HYPOTHYROXINEMIA OF
PREGNANCY
Isolated hypothyroxinemia (IH) of pregnancy is defined as a
free thyroxine level below normal with a normal TSH level in a
thyroid antibody negative woman. Whether or not to treat IH is
even more controversial than whether or not to treat subclinical
hypothyroidism. As there have been no studies demonstrating
improved outcome in treating IH during pregnancy, I do not
begin levothyroxine in this group of women. This is consistent
with the American Thyroid Association Guidelines, which do not
recommend levothyroxine for IH of pregnancy (14). However,
both the Endocrine Society Guidelines and the European Thyroid
Association Guidelines state that levothyroxine intervention can
be considered, especially for IH diagnosed in the first trimester
(15, 25). In those instances where levothyroxine is initiated during
pregnancy, my recommendation would be to discontinue the
levothyroxine immediately postpartum. Follow-up testing post-
partum is not indicated.
IMPACT OF POSTPARTUM THYROIDITIS
Postpartum thyroiditis is defined as thyroid hormone dysfunction
in the initial postpartum year in women who were euthyroid prior
to pregnancy (31). In its classic triphasic form, a hyperthyroid
phase occurs between 1 and 3months postpartum, followed by
a hypothyroid phase between 3 and 9months postpartum, with
a return to the euthyroid state by the end of the first postpartum
year. The vast majority of women who develop PPT are thyroid
antibody positive prior to pregnancy. Interestingly, two studies
have demonstrated that PPT can also develop in women who had
Hashimoto’s thyroiditis prior to pregnancy and who already were
being treated with levothyroxine (32, 33). For PPT to occur in this
group of women, it must be assumed that although levothyroxine
is needed to retain the euthyroid state, thewoman still had residual
functioning thyroid tissue. It is therefore the remaining thyroid
tissue that experiences thyroiditis in the postpartum resulting in
alterations in thyroid function.
The potential for PPT complicates the postpartum manage-
ment of thyroid antibody positive women who are first identified
during pregnancy as requiring thyroid hormone replacement. As
this represents the majority of women who will begin levothy-
roxine during gestation, the postpartum management must take
into account the possibility of PPT. This could result in a scenario
in which a woman started on levothyroxine during gestation for
subclinical hypothyroidism presents with hyperthyroidism in the
first couple of months, only to be followed by hypothyroidism
(potentially quite pronounced) later in the first postpartum year.
Furthermore, many women with PPT present solely with either
a hyperthyroid or hypothyroid phase Therefore, it is critical to
evaluate for PPT when managing postpartum women who were
started on levothyroxine during pregnancy.
CONCLUSION
In conclusion, due to an increased appreciation of the relationship
between thyroid disease and maternal/fetal adverse outcomes,
TABLE 1 | Recommendations for the postpartum management of levothy-
roxine in women who had levothyroxine initiated during pregnancy.
Diagnosis in pregnancy Postpartum treatment
recommendation
Postpartum
testing
Overt hypothyroidism 2/3 of final LT4 dose 6weeks
Subclinical hypothyroidism 1/2 of final LT4 dose 6weeks
Thyroid antibody positive
Subclinical hypothyroidism If last dose 25mcg, D/C
LT4 postpartum
6weeks
Thyroid antibody negative
If last dose 50mcg, start
25mcg postpartum
6weeks
If last dose 75–100mcg,
start 50mcg postpartum
6weeks
If last dose >100mcg, start
50mcg/day final dose
Isolated hypothyroxinemia D/C LT4 postpartum Not recommended
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the number of women identified during pregnancy with thyroid
dysfunction and initiated on levothyroxine therapy is increas-
ing. The postpartum management of these women depends on
multiple factors including the degree of hypothyroidism at diag-
nosis, the maximum dose of levothyroxine required to maintain
the euthyroid state during pregnancy, the presence or absence
of thyroid antibodies, and whether or not PPT occurs. The
recommendations included within this article (Table 1) are based
on the physiological changes, which occur during pregnancy and
the postpartum to the thyroid gland, and the clinical experience
of the author. Prospective management trials are needed to eval-
uate the recommendations made within this manuscript and to
determine optimal treatment of thyroid disease postpartum in
women who had levothyroxine initiated during pregnancy.
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